Modality
siRNA
MOA
GLP-1ag
Target
EZH2
Pathway
Lipid Met
CholangiocarcinomaIPFMeso
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Nov 2025
Phase 1Current
NCT08951436
489 pts·Meso
2018-02→2025-11·Not yet recruiting
NCT04088322
1,985 pts·IPF
2024-12→TBD·Terminated
2,474 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-135mo agoBTD· Meso
2025-11-214mo agoPh2 Data· Meso
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P1/2
Not yet…
P1/2
Termina…
Catalysts
BTD
2025-11-13 · 5mo ago
Meso
Ph2 Data
2025-11-21 · 4mo ago
Meso
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08951436 | Phase 1/2 | Meso | Not yet recr... | 489 | Mayo |
| NCT04088322 | Phase 1/2 | IPF | Terminated | 1985 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| CRS-184 | CRISPR Therapeutics | Phase 1/2 | AHR | |
| Polazanubrutinib | Tango Ther | Phase 1 | IL-17A | |
| Voxabrutinib | Annexon | Phase 1/2 | EZH2 |